Saturnus Bio

About Saturnus Bio

Saturnus Bio is a research-stage biotechnology company launched in June 2026, focused on developing precision medicines for rare monogenic cardiomyopathies—severe heart muscle diseases caused by single-gene defects. The company was founded by life sciences venture capital firm Versant Ventures in a strategic collaboration with the German pharmaceutical company Merck KGaA. This partnership was structured as a "build-to-buy" agreement, a model Versant has successfully used with other major pharmaceutical partners. The company's formation is based on a research-stage collaboration with Merck KGaA, which provided $50 million in upfront funding. This investment gives Merck a minority equity stake and an exclusive option to acquire Saturnus at a predetermined price, contingent on the achievement of certain preclinical milestones and success-based earnouts. This structure allows Merck to foster the development of a specialized pipeline in precision cardiology, an area where it previously had limited presence, while mitigating early-stage risk. For Saturnus, the model provides significant initial funding and a clear path toward acquisition. Saturnus Bio's therapeutic focus is on creating a portfolio of treatments that use targeted gene modulation to address the underlying genetic drivers of inherited cardiomyopathies. These conditions, such as those caused by mutations in genes like MYBPC3 and LMNA, often lead to heart failure and have few effective treatment options beyond managing symptoms. The company aims to develop first-in-class medicines, although the specific gene targets and therapeutic modalities, such as siRNA or base editing, have not been publicly disclosed. The entire pipeline is currently in the preclinical research phase. The company is led by CEO Rick Dewey, MD, who is also an entrepreneur-in-residence at Versant Ventures. His background includes roles at Foresite Labs and the Regeneron Genetics Center, providing deep expertise in human genetics that directly aligns with the company's mission. The discovery research is headed by Russell Miller, Ph.D., who previously led cardiometabolism research at Pfizer, where he focused on rare cardiomyopathies.